Tegaserod
CAS No. 145158-71-0
Tegaserod( —— )
Catalog No. M35455 CAS No. 145158-71-0
Tegaserod is an orally available 5-HT4R agonist and 5-HT2B receptor antagonist with inhibitory effects on various 5-hydroxytryptamine receptors. Tegaserod has antitumor activity and is used in the treatment of irritable bowel syndrome (IBS).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTegaserod
-
NoteResearch use only, not for human use.
-
Brief DescriptionTegaserod is an orally available 5-HT4R agonist and 5-HT2B receptor antagonist with inhibitory effects on various 5-hydroxytryptamine receptors. Tegaserod has antitumor activity and is used in the treatment of irritable bowel syndrome (IBS).
-
DescriptionTegaserod is an orally active serotonin receptor 4 (HTR4; 5-HT4R) agonist and a 5-HT2B receptor antagonist. Tegaserod has pKis of 7.5, 8.4 and 7.0 for human recombinant 5-HT2A, 5-HT2B and 5-HT2C receptors, respectively. Tegaserod causes tumor cell apoptosis, blunts PI3K/Akt/mTOR signaling and decreases S6 phosphorylation. Tegaserod has anti-tumor activity and has the potential for irritable bowel syndrome (IBS) research.
-
In VitroApoptosis Analysis Cell Line:A375, RPMI-7951 (RPMI), SH4, B16F10, MeWo and MEL-JUSO Concentration:3, 5 μM Incubation Time:24, 48, 72 hResult:There was a significant time and dose-dependent increase in apoptosis in all cell lines.Western Blot Analysis Cell Line:RPMI, SH4 and B16F10 cells Concentration:3, 5 μM Incubation Time:8 or 18?h Result:Decreased phosphorylation of the kinase directly upstream of S6, p70 S6 at Thr421/Ser424.
-
In VivoAnimal Model:C57BL/6?J mice were subcutaneously injected with B16F10 cells Dosage:5?mg/kg Administration:Administered intraperitoneally (i.p.) daily for five consecutive days Result:Treatment significantly decreased tumor growth and resulted in only slight decreases in weight following treatment.Animal Model:Female C57BLKS/J db/db miceDosage:0.1, 0.5, 1.0, 2.0 mg/kg Administration:IP 15 min prior to gastric loading Result: Produced a dramatic decrease in the fraction of the meal remaining in the stomach for doses as low as 0.1 mg/kg (0.1 mg/kg). Accelerated gastric emptying, with a reduction of nearly 80% in the fraction remaining at 30 min (P < 0.0001) (0.1 mg/kg).Induced a significant decrease in the gastric emptying rate as the amount of the meal remaining at 30 min was significantly greater (2.0 mg/kg).Resulted in inhibition of tegaserod-induced increased gastric emptying (0.1 mg/kg).
-
Synonyms——
-
PathwayGPCR/G Protein
-
Target5-HT Receptor
-
Recptor5-HT Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number145158-71-0
-
Formula Weight301.39
-
Molecular FormulaC16H23N5O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (165.90 mM; Ultrasonic )
-
SMILESN=C(NN=CC1=CNC=2C=CC(OC)=CC12)NCCCCC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wei Liu, et al. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications. J Exp Clin Cancer Res. 2020 Feb 21;39(1):38.?
molnova catalog
related products
-
EMD-281014
EMD-281014 (Pruvanserin, LSN2411347, LY-2422347) is a potent, highly selective 5-HT2A antagonist with Ki of 0.87 nM.
-
BF-1
BF-1 is a novel selective 5-HT2 receptor antagonist that acts by blocking neurogenic dural plasma protein extravasation induced by mCPP or BW723C86.BF-1 is used in the study of migraine.
-
Landipirdine
A novel 5-HT receptor antagonist for the treatment of Parkinson's disease.
Cart
sales@molnova.com